Kratom Leaf Extract Shows Anti-Inflammatory and Antispasmodic Effects in Mouse Ulcerative Colitis Model

Why it matters

First preclinical evidence that mitragynine-rich kratom leaf extract may alleviate inflammatory bowel disease symptoms through multiple mechanisms, relevant for patients seeking alternative treatments for ulcerative colitis.

The big picture

While whole-leaf kratom remains unregulated in the U.S., researchers have demonstrated its active alkaloid mitragynine modulates immune responses and reduces inflammation in animal models of inflammatory bowel disease. This peer-reviewed study directly tests kratom's traditional use for gastrointestinal conditions.

Key findings

• Kratom extract at 10-20 mg/kg mitragynine significantly reduced disease activity index, colonic lesions, and inflammatory cytokines (TNF-α and IL-1β) in acetic acid-induced colitis mice
• Mitragynine acts through μ-opioid receptor signaling to relax colonic smooth muscle and reduce intestinal spasms
• Kratom treatment increased macrophage phagocytic activity and reduced oxidative stress markers (MDA and NO) in inflamed tissue
• Blood parameters improved with kratom treatment: red blood cells increased, white blood cell count decreased, suggesting immune modulation
• Treated mice showed restored food intake, body weight gains, and higher survival rates compared to untreated colitis controls

What they say

The researchers concluded: "Kratom leaf extract, which contains mitragynine, alleviated acetic acid-induced colitis in mice by modulating immune responses and by its anti-inflammatory, antioxidative, and antispasmodic effects. Therefore, kratom leaves may be an effective therapeutic candidate for subsequent development as a multitarget drug for UC."

Bottom line

**First peer-reviewed study to demonstrate kratom's anti-inflammatory effects in inflammatory bowel disease, opening potential therapeutic development pathway for ulcerative colitis treatment.**